Robert McEwen

4.4k total citations · 1 hit paper
37 papers, 2.2k citations indexed

About

Robert McEwen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Robert McEwen has authored 37 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 16 papers in Molecular Biology. Recurrent topics in Robert McEwen's work include Advanced Breast Cancer Therapies (9 papers), Cancer Genomics and Diagnostics (9 papers) and Lung Cancer Treatments and Mutations (7 papers). Robert McEwen is often cited by papers focused on Advanced Breast Cancer Therapies (9 papers), Cancer Genomics and Diagnostics (9 papers) and Lung Cancer Treatments and Mutations (7 papers). Robert McEwen collaborates with scholars based in United Kingdom, United States and Spain. Robert McEwen's co-authors include Robert H. Michell, Stephen K. Dove, Jonathan R. Dry, J. Carl Barrett, Brian Dougherty, Peter J. Parker, Frank T. Cooke, Zhongwu Lai, Andrew B. Holmes and Aleksandra Markovets and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Robert McEwen

37 papers receiving 2.2k citations

Hit Papers

VarDict: a novel and versatile variant caller for next-ge... 2016 2026 2019 2022 2016 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research
    2016 497 citations Zhongwu Lai, Aleksandra Markovets et al. Nucleic Acids Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert McEwen United Kingdom 20 1.1k 651 613 566 495 37 2.2k
Ari Hashimoto Japan 25 1.4k 1.2× 379 0.6× 588 1.0× 643 1.1× 126 0.3× 47 2.3k
Yong Wan United States 26 1.6k 1.4× 323 0.5× 621 1.0× 366 0.6× 159 0.3× 45 2.2k
Lori S. Hart United States 19 1.1k 1.0× 404 0.6× 527 0.9× 356 0.6× 230 0.5× 27 1.8k
Thomas Botton France 12 1.2k 1.1× 702 1.1× 821 1.3× 182 0.3× 354 0.7× 14 2.1k
Zuzana Hořejšı́ United Kingdom 16 3.3k 2.9× 674 1.0× 1.6k 2.6× 489 0.9× 121 0.2× 19 3.8k
David Santamarı́a Spain 21 2.3k 2.0× 452 0.7× 1.5k 2.4× 753 1.3× 727 1.5× 43 3.3k
Eric S. Martin United States 24 1.6k 1.4× 386 0.6× 578 0.9× 166 0.3× 191 0.4× 57 2.7k
Bryan Serrels United Kingdom 25 1.4k 1.2× 309 0.5× 621 1.0× 967 1.7× 129 0.3× 37 2.6k
Masaru Niki Japan 21 2.2k 2.0× 512 0.8× 840 1.4× 306 0.5× 537 1.1× 27 3.4k
Yosef Landesman United States 33 2.5k 2.2× 303 0.5× 935 1.5× 112 0.2× 340 0.7× 171 3.2k

Countries citing papers authored by Robert McEwen

Since Specialization
Citations

This map shows the geographic impact of Robert McEwen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert McEwen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert McEwen more than expected).

Fields of papers citing papers by Robert McEwen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert McEwen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert McEwen. The network helps show where Robert McEwen may publish in the future.

Co-authorship network of co-authors of Robert McEwen

This figure shows the co-authorship network connecting the top 25 collaborators of Robert McEwen. A scholar is included among the top collaborators of Robert McEwen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert McEwen. Robert McEwen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, J-Y., Funda Meric‐Bernstam, Ana Oaknin, et al.. (2025). 145P Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analysis of DESTINY-PanTumor02 (DP-02) Part 1. Annals of Oncology. 36. S251–S252. 1 indexed citations
2.
3.
4.
5.
Lipsyc-Sharf, Marla, Elza C. de Bruin, Robert McEwen, et al.. (2022). Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer. Journal of Clinical Oncology. 40(22). 2408–2419. 85 indexed citations
6.
Shire, Norah J., Alyssa Klein, Asieh Golozar, et al.. (2020). STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world. PLoS ONE. 15(9). e0238358–e0238358. 54 indexed citations
7.
Golozar, Asieh, Jenna Collins, Kathy Fraeman, et al.. (2019). OA07.02 LKB1 Mutations in Metastatic Non-Small Cell Lung Cancer (mNSCLC): Prognostic Value in the Real World. Journal of Thoracic Oncology. 14(10). S223–S224. 4 indexed citations
8.
Michaloglou, Chrysiis, Claire Crafter, Rasmus Siersbæk, et al.. (2018). Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer. Molecular Cancer Therapeutics. 17(5). 908–920. 128 indexed citations
9.
Lynch, James T., Urszula M. Polanska, Oona Delpuech, et al.. (2017). Inhibiting PI3Kβ with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors. Clinical Cancer Research. 23(24). 7584–7595. 24 indexed citations
10.
Ichihara, Eiki, David Westover, Catherine B. Meador, et al.. (2017). SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Cancer Research. 77(11). 2990–3000. 104 indexed citations
11.
Hudson, Kevin, Urs J. Hancox, Cath Trigwell, et al.. (2016). Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA -Dependent Breast Cancers. Molecular Cancer Therapeutics. 15(5). 877–889. 36 indexed citations
12.
Carr, T. Hedley, Robert McEwen, Brian Dougherty, et al.. (2016). Defining actionable mutations for oncology therapeutic development. Nature reviews. Cancer. 16(5). 319–329. 77 indexed citations
13.
Lai, Zhongwu, Aleksandra Markovets, Miika Ahdesmäki, et al.. (2016). VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Research. 44(11). e108–e108. 497 indexed citations breakdown →
14.
Guichard, Sylvie M., Jon Curwen, Teeru Bihani, et al.. (2015). AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules. Molecular Cancer Therapeutics. 14(11). 2508–2518. 103 indexed citations
15.
Sidders, Ben S., Alex Gutteridge, Lee Harland, et al.. (2014). Precompetitive activity to address the biological data needs of drug discovery. Nature Reviews Drug Discovery. 13(2). 83–84. 12 indexed citations
16.
Guinney, Justin, Charles Ferté, Jonathan R. Dry, et al.. (2013). Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients. Clinical Cancer Research. 20(1). 265–272. 30 indexed citations
17.
Dove, Stephen K., Robert McEwen, Andrew E. Mayes, et al.. (2002). Vac14 Controls PtdIns(3,5) P 2 Synthesis and Fab1-Dependent Protein Trafficking to the Multivesicular Body. Current Biology. 12(11). 885–893. 112 indexed citations
18.
McEwen, Robert, Stephen K. Dove, Frank T. Cooke, et al.. (1999). Complementation Analysis in PtdInsPKinase-deficient Yeast Mutants Demonstrates ThatSchizosaccharomyces pombe and Murine Fab1p Homologues Are Phosphatidylinositol 3-Phosphate 5-Kinases. Journal of Biological Chemistry. 274(48). 33905–33912. 92 indexed citations
19.
McEwen, Robert & Thomas W. Young. (1998). Secretion and pH-dependent self-processing of the pro-form of the Yarrowia lipolytica acid extracellular protease. Yeast. 14(12). 1115–1125. 6 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ari Hashimoto Breakdown of academic impact, for papers by Yong Wan Breakdown of academic impact, for papers by Lori S. Hart Breakdown of academic impact, for papers by Thomas Botton Breakdown of academic impact, for papers by Zuzana Hořejšı́ Breakdown of academic impact, for papers by David Santamarı́a Breakdown of academic impact, for papers by Eric S. Martin Breakdown of academic impact, for papers by Bryan Serrels Breakdown of academic impact, for papers by Masaru Niki Breakdown of academic impact, for papers by Yosef Landesman
Rankless by CCL
2026